Welcome to our dedicated page for KIORA PHARMACEUTICALS SEC filings (Ticker: KPHMW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KIORA PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KIORA PHARMACEUTICALS's regulatory disclosures and financial reporting.
Kiora Pharmaceuticals director Erin Parsons reported a compensation-related stock option grant. She received options to buy 25,000 shares of Kiora common stock at an exercise price of $2.63 per share under the company’s 2024 Equity Incentive Plan.
The options will become fully exercisable on June 10, 2027 and expire on June 10, 2036. After this grant, Parsons holds options covering 25,000 shares. This is an award, not an open-market purchase or sale of stock.
Kiora Pharmaceuticals director David Hollander received a grant of stock options as compensation. He was awarded options covering 25,000 shares of common stock at an exercise price of $2.63 per share, issued under the company’s 2024 Equity Incentive Plan.
The options will become fully exercisable on June 10, 2027 and are scheduled to expire on June 10, 2036 if not exercised. After this grant, Hollander holds 25,000 stock options directly, giving him potential future ownership if the options are exercised.
Kiora Pharmaceuticals director Lisa Walters-Hoffert received a grant of stock options as part of her compensation. She was awarded 25,000 options to buy Kiora common stock at an exercise price of $2.63 per share under the company’s 2024 Equity Incentive Plan.
The options were granted at no cost and relate to 25,000 underlying shares of common stock. They will become fully exercisable on June 10, 2027 and will expire on June 10, 2036 if not exercised. After this grant, she holds 25,000 options directly, and the filing reports no open-market purchases or sales.
Kiora Pharmaceuticals director Praveen Tyle received a grant of stock options as equity compensation. The award covers options on 40,000 shares of common stock at an exercise price of $2.63 per share under the 2024 Equity Incentive Plan.
The options become fully exercisable on June 10, 2027 and expire on June 10, 2036. Following this grant, Tyle holds options on 40,000 shares directly, with no open-market buying or selling reported in this filing.
Kiora Pharmaceuticals, Inc. is registering 11,797,088 shares of Common Stock for resale by selling stockholders.
The registration covers (i) 438,471 shares issued in a Private Placement, (ii) 1,527,710 shares underlying pre-funded warrants, (iii) 7,864,726 shares underlying Tranche A-1 warrants, and (iv) 1,966,181 shares underlying Tranche A-2 warrants. The Company is not offering any shares for its own account and will receive no proceeds from resales; however, the Company would receive proceeds from any warrant cash exercises. The prospectus states that the registered securities represent approximately 72.7% of outstanding common stock as of May 14, 2026 after giving effect to the registered underlying shares. The resale may occur from time to time through public or private transactions as described in the Plan of Distribution.
Kiora Pharmaceuticals, Inc. reports that Nantahala Capital Management, LLC and its principals, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 438,469 shares of common stock as of March 31, 2026. The filing states those shares represent 9.99% of the outstanding common stock and that the 438,469 shares include shares issuable upon exercise of convertible securities within sixty days. The reporting persons disclose shared voting and dispositive power over the 438,469 shares. A fund advised by Nantahala, BLACKWELL PARTNERS LLC - SERIES A, is identified as having the right to receive dividends or sale proceeds on more than 5% of those shares.
KIORA PHARMACEUTICALS, INC. filing: Alyeska Investment Group and related filers report 394,668 shares beneficially owned, representing 9.99% of Common Stock as of March 31, 2026. The position equals the maximum exercisable under a beneficial ownership limitation tied to warrants.
The filing states the Reporting Persons hold warrants exercisable for 596,854 shares, but the 9.99% limitation permits exercise of only 394,668 shares based on 3,950,628 shares outstanding per the Form 10-K dated March 25, 2026. Voting and investment control is exercised by Alyeska Investment Group, L.P.; Anand Parekh is named but disclaims beneficial ownership.
Kiora Pharmaceuticals reported that Nantahala Capital Partners LP amended its Schedule 13G to state beneficial ownership of 148,736 shares as of March 31, 2026. The filing notes those 148,736 shares include shares acquirable upon exercise of warrants within sixty days. The position represents 3.388% of the class, based on 4,431,940 shares outstanding as of the 10-Q filed May 8, 2026.
Kiora Pharmaceuticals, Inc. reported a net loss of $2.4 million for the three months ended March 31, 2026, compared with $2.2 million a year earlier, as it continues investing in ophthalmic drug development.
Total operating expenses were $2.5 million, including $1.6 million in general and administrative costs and $2.1 million in research and development, partly offset by $1.2 million of collaboration credits tied to the KIO‑301 program. Other income, mainly interest, added $0.1 million.
At March 31, 2026, Kiora held $11.0 million in cash and cash equivalents and $2.9 million in short‑term investments, with total assets of $21.2 million and stockholders’ equity of $13.9 million. Management states that, including $5 million raised in an April 2026 private placement and reimbursement of all KIO‑301 expenses by partner Théa Open Innovation, current resources are expected to fund planned operations into late 2028.
Kiora Pharmaceuticals is asking stockholders to vote at its 2026 annual meeting on director elections, executive pay, auditor ratification, and an equity plan increase. Three Class II directors are nominated to serve until 2029. Investors will cast a non-binding advisory vote on 2025 compensation for the CEO and other named executives, and on retaining Haskell & White LLP as independent auditor for 2026. The company also seeks approval to amend its 2024 Equity Incentive Plan to add 1,500,000 shares for future equity awards. As of the April 16, 2026 record date, 4,432,440 common shares were outstanding, each with one vote.